Romosozumab
Amgen hit by major safety blow on osteoporosis drug
May 22, 2017Research and Development, Sales and Marketing Amgen, Romosozumab, UCB SA
Amgen and UCB SA have been delivered a crushing blow in its attempt to have a drug for osteoporosis approved …
Further positive trial results boost Amgen and UCB’s romosozumab
March 21, 2016Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval
Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …
UCB targets regulatory filing for its osteoporosis drug in 2016
March 3, 2016Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis
Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
Amgen and UCB announce positive romosozumab results
February 22, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis
Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
